Call (844) 879-2237

Home » News » Acera Surgical to Present Results of Study on the Use of Restrata™ Wound Matrix in Healing Full-thickness Wounds at Fall Symposium on Advanced Wound Care

Acera Surgical to Present Results of Study on the Use of Restrata™ Wound Matrix in Healing Full-thickness Wounds at Fall Symposium on Advanced Wound Care

St. Louis, MO—August 29, 2017— Acera Surgical Inc., a pioneer in regenerative medicine, has been selected to present the results from a study involving the Restrata™ Wound Matrix at the Fall 2017 Symposium on Advanced Wound Care (“SAWC”), being held in Las Vegas, Nevada, from October 20-22. SAWC is one of the nation’s largest and most well-respected interdisciplinary wound care programs.  This presentation offers Acera the opportunity to present its preclinical data to more than 1300 participants, including practitioners, researchers and key opinion leaders.

The study, titled “Comparison of a Fully Synthetic Electrospun Matrix to a Bi-Layered Xenograft in Healing Full Thickness Cutaneous Wounds in a Porcine Model,” demonstrates Restrata™’s  ability to accelerate healing and closure of full-thickness wounds and to increase the amount and maturity of granulation tissue and neovascularization compared to a leading biologic skin substitute.

Restrata™ is the second product in Acera’s portfolio of fully synthetic electrospun matrices that address the shortcomings of conventional biologic-based products.  “Restrata™ offers a new approach in the treatment of acute and chronic wounds,” said Dr. Matthew MacEwan, Chief Scientific Officer of Acera Surgical. “Due to the structural similarities between Restrata™’s synthetic nanofibers and native extracellular matrix, cells are able to easily infiltrate and proliferate throughout our material resulting in tissue regeneration.”

About Acera Surgical Inc.

Acera Surgical Inc.  (“Acera,” St. Louis, Missouri) is a bioscience company developing and commercializing a portfolio of fully synthetic electrospun scaffolds for regenerative medical applications. Acera’s products exhibit a structure similar to native extracellular matrix (ECM) and thus support rapid and effective healing. The FDA cleared Acera’s first product, Cerafix® Dura Substitute, in 2016 and its second product, Restrata™ Wound Matrix, in 2017, both via 510(k), granting commercial access to markets exceeding $1.2B in revenue.  Acera is currently raising Series A financing and seeking commercialization partners.

For additional information on Acera Surgical or the Restrata™ Wound Matrix, please visit http://www.acera-surgical.com.

Comments are closed.

http://acera-surgical.com